Lunch Wrap: ASX takes profits as GemLife pops on IPO debut, Santa Fe surges 300pc
GemLife pops 20pc in biggest float of the year
Microsoft cuts jobs, wild Fed rumour denied
The ASX took a step back on Thursday, down 0.5% by lunch in the east after setting a fresh record yesterday.
Overnight on Wall Street, the Dow slipped 0.1%, but Nasdaq rose 0.8% and the S&P 500 hit a new record thanks to a fresh Vietnam trade pact that had Trump puffing his chest.
Elsewhere, Microsoft is swinging the axe again. Around 120 Aussie jobs are set to go as part of its latest global cull of 9,000 roles.
Meanwhile, one particularly wild rumour suggested Scott Bessent could take on double duty as both Fed Chair and Treasury Secretary.
The White House shot it down immediately as 'absolutely fake news', noting the roles were officially split back in 1935.
And over in US Congress, the House is sprinting to pass Trump's 'Big Beautiful Bill' before the July 4 deadline.
A few Republican holdouts have flipped their votes, including Ohio's Warren Davidson, who now says the bill includes 'major wins'.
Back home, though, after a strong week, local punters seem to be taking profits this morning.
Retailers like JB HiFi (ASX:JBH) and Wesfarmers (ASX:WES) fell, giving back recent gains sparked by talk of a possible RBA rate cut.
Miners, on the other hand, found their second wind.
China's leadership has apparently had enough of its steel sector eating itself alive with lowball pricing.
Xi Jinping's crew came out swinging this week, promising to crack down on 'disorderly' price competition and shut the door on excess industrial capacity.
That gave iron ore a kick, and sent the ASX miners roaring this week, including today.
Lithium names followed suit. Pilbara Minerals (ASX:PLS) jumped 8%, Mineral Resources (ASX:MIN) rose 6.5% this morning.
And on the IPO front, GemLife Communities Group (ASX:GLF) has just made its grand entrance.
The over-50s luxury resort developer opened at around $5, a 20% premium on its $4.16 IPO price, a tidy win on the year's biggest float.
The $750 million raise comes courtesy of the Puljich family and Singapore's Thakral Capital, joining a busy IPO season that's already seen Virgin Australia (ASX:VGN), Tetratherix (ASX:TTX) and the Twiggy-backed Greatland Resources (ASX:GGP) hit the boards.
In large caps news, ProMedicus (ASX:PME) leapt 6% and touched its all-time high after landing two juicy US imaging contracts worth nearly $200 million.
Elsewhere, AMP (ASX:AMP) is back in court.
Two new legal proceedings – one in Victoria over super insurance fees, and another in NSW tied to the Macquarie Shopping Centre sale – have landed on the company's desk.
AMP says it will defend both.
ASX SMALL CAP WINNERS
Here are the best performing ASX small cap stocks for July 3 :
Security Description Last % Volume MktCap
SFM Santa Fe Minerals 0.145 368% 1,445,835 $2,257,382
OKJ Oakajee Corp Ltd 0.031 55% 297,791 $1,828,921
AXP AXP Energy Ltd 0.002 50% 45,000 $6,684,681
PAB Patrys Limited 0.002 50% 4,369,649 $2,365,810
AGY Argosy Minerals Ltd 0.026 37% 14,785,349 $27,662,498
AMS Atomos 0.004 33% 1,000,000 $3,645,055
PLG Pearlgullironlimited 0.008 33% 8,200 $1,227,251
WR1 Winsome Resources 0.160 25% 1,234,147 $31,096,415
EQS Equitystorygroupltd 0.025 25% 175,992 $3,336,408
AOK Australian Oil. 0.003 25% 5,785,563 $2,003,566
CUL Cullen Resources 0.005 25% 2,837,583 $2,773,607
KPO Kalina Power Limited 0.005 25% 3,532,455 $11,731,983
THR Thor Energy PLC 0.010 25% 1,103,950 $5,686,319
WBE Whitebark Energy 0.005 25% 200,000 $2,749,334
OAK Oakridge 0.080 23% 375 $1,754,864
REZ Resourc & En Grp Ltd 0.022 22% 514,252 $12,089,504
THB Thunderbird Resource 0.011 22% 5,863,549 $3,507,673
NSB Neuroscientific 0.140 22% 769,105 $38,246,206
PAR Paradigm Bio. 0.465 21% 1,185,593 $149,930,097
CRN Coronado Global Res 0.163 20% 19,430,895 $226,321,254
WYX Western Yilgarn NL 0.030 20% 261,891 $3,439,027
BNL Blue Star Helium Ltd 0.006 20% 46,483 $13,474,426
CCO The Calmer Co Int 0.003 20% 6,010,228 $7,528,383
PRM Prominence Energy 0.003 20% 2,000,001 $1,216,176
Santa Fe Minerals (ASX:SFM) jumped more than 300% after locking in a deal to acquire the Eburnea Gold Project from Turaco Gold, giving it 100% of the granted Satama Permit and up to 90% of the nearby Bouake North Application once granted. Satama's already shown promise, with hits like 26m at 4.82g/t gold, and sits on a 2km-long mineralised zone with plenty of room to grow.
Geophysics suggests multiple parallel zones still to be drilled, and the Bouake prospect lies just 35km from Endeavour's 3Moz Lafigue mine. To fund the move, Santa Fe has secured $1.2 million at 5c a share, a chunky 61% premium, all subject to shareholder and ASX sign-off. If this plays out as planned, Santa Fe said it could be a big step for the company into West African gold.
Australian Oil Company (ASX:AOK) has settled with ex-director Gary Jeffery and his company Dungay Resources, wiping a $1 million loan and over $180k in interest from AOK's books. In return, it will pay $28,000 in cash and issue 36 million shares to cover historical director fees. The deal follows a broader management review, and is aimed at strengthening the balance sheet and moving forward with plans to grow its Californian operations.
Resources and Energy Group (ASX:REZ) has secured firm commitments to raise $1.1 million at 1.5c a share, a 16.7% discount to the last trade. The cash will go towards expanding its vat leach facility, ramping up gold production at Maranoa, and drilling across its East Menzies project. The raise saw strong backing. A third gold pour is on the way, and approval for more vats is pending.
ASX SMALL CAP LOSERS
Here are the worst performing ASX small cap stocks for July 3 :
Code Name Price % Change Volume Market Cap
EEL Enrg Elements Ltd 0.001 -50% 1 $6,507,557
ADY Admiralty Resources. 0.005 -29% 100,000 $18,406,356
DGR DGR Global Ltd 0.004 -27% 100,000 $5,740,328
CDE Codeifai Limited 0.059 -26% 18,615,441 $35,435,076
CAV Carnavale Resources 0.003 -25% 6,237,500 $16,360,874
KLR Kaili Resources Ltd 0.006 -25% 14,599 $1,179,203
BYH Bryah Resources Ltd 0.009 -25% 6,068,163 $10,439,442
MPP Metro Perf.Glass Ltd 0.050 -24% 51,732 $12,234,954
WWG Wisewaygroupltd 0.145 -22% 8,140 $30,960,341
VEN Vintage Energy 0.004 -20% 5,068,952 $10,434,568
ID8 Identitii Limited 0.005 -17% 729,200 $4,668,081
TEG Triangle Energy Ltd 0.003 -17% 421,996 $6,267,702
HMD Heramed Limited 0.011 -15% 3,025,217 $11,382,836
AS2 Askarimetalslimited 0.006 -14% 73,792 $2,829,195
BLU Blue Energy Limited 0.006 -14% 835,489 $12,956,815
REC Rechargemetals 0.013 -13% 664,404 $3,854,850
RMI Resource Mining Corp 0.013 -13% 835,624 $11,016,800
NAG Nagambie Resources 0.015 -12% 82,482 $13,656,140
MTC Metalstech Ltd 0.115 -12% 744 $27,133,811
SUH Southern Hem Min 0.031 -11% 226,806 $25,768,402
TAT Tartana Minerals Ltd 0.031 -11% 8,968 $7,495,106
UVA Uvrelimited 0.120 -11% 289,914 $8,127,000
HTG Harvest Tech Grp Ltd 0.016 -11% 452,204 $16,127,041
RR1 Reach Resources Ltd 0.008 -11% 61,118 $7,869,882
IN CASE YOU MISSED IT
Resolution Minerals (ASX:RML) is wasting no time starting exploration at its Horse Heaven project in the US, a historical producer of strategically important metals antimony and tungsten.
Silver Mines (ASX:SVL) has completed acquisition of the Calico North silver project and kicked off an earn-in at the Kramer Hills gold and silver project in California.
StockTake: Many Peaks Minerals (ASX:MPK) has expanded its gold play in west Africa with the addition an exploration permit south of the company's Ferké.
Drilling at Brightstar Resources' (ASX:BTR) Sandstone Hub has returned high-grade gold hits that highlight its tremendous exploration potential.
Australian tech company Codeifai (ASX:CDE) has appointed industry leaders from OpenAI, Google, Binance and WhatsApp to spearhead growth plans.
RareX (ASX:REE) has found a 70m heavy rare earths bearing vein at its Mt Mansbridge project in WA, just down the road from the 11.7Mt Browns Range project.
LAST ORDERS
Finder Energy (ASX:FDR) has closed a $6m placement early due to strong support, with major shareholder Longreach Capital Investment committing to $2.7m.
FDR will channel the new funds to bring the Kuda Tasi and Jahal oil development project to a final investment decision and support the transition to an offshore development company, targeting first oil in 2027.
Western Yilgarn (ASX:WYX) has brought former WA government director Darren Foster onto the board as a non-executive director, leveraging his extensive expertise in environmental approvals, sustainable development and stakeholder engagement.
Foster has previously served as the deputy director general of the WA department of fisheries, as director of the environmental protection authority and most recently as director general of the department of the premier and cabinet.
At Stockhead, we tell it like it is. While Finder Energy and Western Yilgarn are Stockhead advertisers, they did not sponsor this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Herald Sun
24 minutes ago
- Herald Sun
IPO Watch: GemLife kicks off with a $750m bang in biggest ASX IPO of the year
IPO market begins to show signs of life as ASIC cuts red tape GemLife hits ASX with $1.6b luxury retirement splash GLF tops Virgin with biggest Aussie float of 2025 For the last couple of years, the Australian IPO market has been on a sabbatical. But now, the country's regulators are rolling out the red carpet, or at least tugging at the red tape, to make the path to public life a little easier. In June, the Australian Securities and Investments Commission (ASIC) kicked off a trial to streamline the IPO process. The plan is to cut a week off the traditional 20-week timeline by reviewing offer documents earlier, and reducing the back-and-forth that tends to slow things down. It's only open to companies worth over $100 million, but the message is clear: Australia wants more listings, and it's willing to loosen its collar to get them. From trailer parks to luxury resorts Just days after Virgin Australia's (ASX:VGN) long-awaited return to the ASX, another float is taking centre stage, this time from the world of luxury over-50s living. On Thursday, GemLife Communities Group (ASX:GLF) officially made its debut on the ASX, becoming the latest major player to test investor appetite in a warming IPO market. The stock opened at $5, a 20% premium to its $4.16 offer price, before easing back to around $4.40 by 3pm, still delivering a solid first-day gain. Founded in 2016, GemLife has grown fast. What started as a joint venture between the Puljich family and Singapore-listed Thakral Corp is now a $1.6 billion business, with a portfolio of resort-style communities built for Australians aged 50 and over. In fact, the story stretches back even further. GemLife CEO Adrian Puljich is carrying on the legacy of his father, Peter Puljich, who arrived in Australia in 1968 from Croatia and later transformed a caravan park on the Gold Coast into a high-end retirement community. 'We are a founder‑led pioneer business,' Adrian Puljich told Bloomberg. 'What makes us so unique is the fact that we build our own product. 'Every single touch point in the life cycle of GemLife Communities is dealt with by the GemLife builder.' That vertical integration, from land acquisition to construction and community operations, is a big part of the group's pitch to investors. All the tailwinds behind it GemLife is at the luxury end of the land‑lease community sector. Residents buy their home (usually prefab‑style), lease the land it sits on, and pay weekly fees of $230–$250 for access to top‑tier amenities. This includes country clubs, cinemas, bowling alleys, pools, pickleball courts, you name it. With properties spread across Queensland, NSW, and Victoria – from Pimpama on the Gold Coast to Woodend in Victoria's Macedon Ranges – GemLife has grown into one of the country's largest operators in this space. The IPO will help fund the $270 million acquisition of eight new projects from a company wholly owned by Adrian Puljich, growing the pipeline to 32 communities and nearly 10,000 homes. It's a big swing, but one that's riding a wave of tailwinds. Australia's population is ageing, home prices are stubbornly high, and many older Australians are looking to downsize without downgrading. That makes land‑lease communities a clever halfway point. According to Colliers, the land‑lease sector is tipped to grow 5% to 7% annually over the next five years, helped by both demand and new developments. Biggest listing so far this year GemLife's float was structured as a stapled security, a common setup in Australia where two or more securities trade together. The IPO raised $750 million, edging out Virgin's $685 million float, and making GLF the largest ASX IPO so far this year. After listing, Adrian Puljich holds about 17.6%, Thakral Capital 16.7%, and Peter Puljich 8.8%. It's a hefty debut in what's been a subdued IPO market. According to the ASX, total Australian IPO proceeds this year were sitting below $150 million prior to Virgin and GemLife's listings. That puts GemLife in rarefied company, and alongside two listed peers in the over‑50s living space – Lifestyle Communities (ASX:LIC) valued at around $870 million, and Ingenia Communities Group (ASX:INA), sitting closer to $2.3 billion. 'Encouraging older Australians to downsize also contributes positively to the broader property market, opening much‑needed family‑sized housing for younger buyers,' said Puljich. Originally published as IPO Watch: GemLife kicks off with a $750m bang in biggest ASX IPO of the year
SBS Australia
24 minutes ago
- SBS Australia
Kremlin: Putin tells Trump Russia will ‘pursue its goals' in Ukraine
Listen to Australian and world news, and follow trending topics with SBS News Podcasts . The Russian government says President Vladimir Putin has reiterated to US President Donald Trump that Russia will keep pushing to solve the conflict's root causes. The comments come as Mr Trump has been pushing for a quick halt to the Ukraine war in a nearly hour long phone call with Mr Putin. Mr Putin's aide says the two leaders did not discuss the U-S decision to halt some weapons shipments to Ukraine during the call. Meanwhile, Ukrainian President Volodymyr Zelenskyy says he hopes to speak to President Trump today (Friday) about the pause in weapons shipment. "We supported it from the very beginning, the idea of President Trump, unconditional ceasefire. I said it not once that we are ready for any kind of format of meeting, and I think that in Russia, only Putin, real decision makers, that's why we need meeting on the level of leaders if we really want peace." Justice advocates in the Australian Capital Territory say the territory's decision to raise the age of criminal responsibility should serve as an example to other states and territories. The ACT has become the first jurisdiction in Australia to raise the age at which a child can be held responsible for a crime to 14. Rather than facing charges, children will now be referred to a therapeutic support panel to help address their offending. Serious crimes such as murder, serious violence and sexual offences will be exempt. Jonathan Hunyor of the Justice and Equity Centre says locking up ten-year-old children only creates worse social problems. "Well the ACT has looked at the evidence, and the ACT is obviously serious about making their community safer because we know that locking up kids makes the community less safe. What locking up kids does is it cruels their chances, it takes them away from positive influences and what they talk about, building social capital... and instead what do is place kids in a situation where they build criminal capital. They go to the university of crime, they get taught that they're criminals." Gaza's health ministry says Israeli airstrikes and shootings have killed 94 Palestinians in Gaza in a single night, including 45 who were attempting to get much-needed humanitarian aid. Five people were killed while outside sites associated with the Gaza Humanitarian Foundation, the privately-run American aid organisation backed by Israel, while 40 others were killed waiting for aid in other locations across the Gaza Strip. 15 people were in strikes that hit tents in the sprawling Mawasi zone, where many displaced Palestinians are sheltering, and a separate strike on a school in Gaza City sheltering displaced people also killed 15 people. Intisar Abu Assi lost her son and daughter in the strikes. "My son and daughter and their children, my children, my children (Camerawoman's asking: How old are the children?) They are all small children, no older than 12, 10, 8, 5, 2 years old, my beloved ones. (Camerawoman's asking: How many people have you lost?) 13 individuals, 13 people from one family." Airlines are being warned to tighten security after a hack affecting millions of Qantas customers leaves the aviation giant exposed to possible legal action. The cyber attack targeted a third-party platform used by one of the airline's call centres, exposing the personal details of up to six million customers. Names, phone numbers, dates of birth and email addresses are among the data believed to be leaked. Legal experts have suggested the incident could lead to a class action in a repeat of compensation claims lodged following major breaches at Optus and Medibank in 2022. Analysts say the Medibank hack could end up costing the health insurer $700 million or more. Gaza's Health Ministry says the number of Palestinians killed in Gaza has passed 57,000, including 223 missing people who have been declared dead since October 7th, 2023. Liverpool fans have paid tribute to star Portuguese forward Diogo Jota, who has died in a car crash near Zamora in northwestern Spain with his brother Andre Silva. According to local authorities, Jota and his brother died when the car they were in veered off the road and burst into flames. Spanish police say evidence at the scene of the crash suggests Jota's car suffered a burst tyre while overtaking. Fans have gathered to honour the player, leaving cards and flowers in his memory. "The way he played football with a smile on his face all the time. He was the epitome of enjoying what you do. Every time he went out on the pitch he gave his all. You don't know these people personally, but when you do lose somebody in this fashion, it's devastating. It's going to affect everyone. It's like losing someone really, really close to you." Jota, who was married on June 28th, helped Liverpool win the Premier League last season and also won the FA Cup and League Cup with the team. (Liverpool Football Club has issued a statement, saying it's devastated by the death of Jota and his brother. The Portuguese Football Federation has also paid tribute to the brothers, saying their deaths are an irreparable loss for Portuguese football.) ***
News.com.au
31 minutes ago
- News.com.au
ASX June Health Winners: Sector falls 1.05pc but Amplia up 300pc after positive trial news
The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY Amplia up 300% in June after complete responses in two advanced (metastatic) pancreatic cancer patients in ACCENT trial While the broader market showed resilience to global geopolitical and economic pressures in June, the ASX 200 Health Care index remained in poor shape, falling 1.05% for the month. The sector remains the worst-performing ASX sector year-to-date and the only one in the red, down 6.64%. Morgans healthcare analyst Iain Wilkie told Stockhead the first half of 2025 had been highly volatile for the global healthcare sector, driven by policy uncertainty in the US. He said Donald Trump's policies were impacting the sector including funding cuts and shakeups to regulatory agencies such as the US Food and Drug Administration (FDA). In addition, Trump is advancing the 'Most Favored Nation' (MFN) drug pricing policy, which seeks to align US prescription medicine prices with the lowest levels paid in other developed nations. While the policy's full implementation remains pending, it has already created uncertainty for pharmaceutical companies, with no clear path yet on how it will be enforced or the potential market ramifications. Wilkie said the sector likely also saw some tax loss selling in June – the final month of the Australian financial year – with many investors crystallising losses in this space to offset gains made in other parts of their portfolios. "We often view this month as a potential opportunity to stock up on some companies at a discount if we continue to see long term value in them and approaching significant catalysts," he said. How ASX biotechs performed in June CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP ATX Amplia Therapeutics 20 300.0% 91.17 NSB Neuroscientific 8.7 50.0% 36.58 OSL Oncosil Medical 120 50.0% 17.06 EZZ EZZ Life Science 234 49.5% 116.05 NYR Nyrada Inc. 24 45.5% 50.62 CGS Cogstate Ltd 174.5 33.7% 295.62 ALA Arovella Therapeutic 10 31.6% 112.91 AHX Apiam Animal Health 52 28.4% 92.89 PEB Pacific Edge 9.6 28.0% 81.19 IRX Inhalerx Limited 3.8 26.7% 7.90 NC6 Nanollose Limited 6.7 26.4% 20.74 VLS Vita Life Sciences 225 23.6% 123.28 SHG Singular Health 37 21.3% 120.68 CSX Cleanspace Holdings 52 20.9% 39.89 IPD Impedimed Limited 3.5 16.7% 79.07 ALC Alcidion Group Ltd 10 16.3% 147.72 IVX Invion Ltd 11 15.8% 8.49 CU6 Clarity Pharma 250 15.7% 763.53 NUZ Neurizon Therapeutic 15.5 14.8% 76.31 ARX Aroa Biosurgery 58 13.7% 193.22 SOM SomnoMed Limited 65 11.1% 138.31 COH Cochlear Limited 30042 10.7% 19,917.31 CTQ Careteq Limited 1.1 10.0% 2.61 ACW Actinogen Medical 2.3 9.5% 73.07 EBR EBR Systems 119.5 7.7% 523.20 DVL Dorsavi Ltd 1.5 7.1% 12.62 PYC PYC Therapeutics 129.5 7.0% 755.32 COV Cleo Diagnostics 39 6.8% 31.82 OCA Oceania Healthc Ltd 63 6.8% 456.27 CMB Cambium Bio Limited 21 5.0% 3.84 IDX Integral Diagnostics 254 5.0% 904.56 RMD ResMed Inc. 3935 3.8% 23,160.79 EMD Emyria Limited 2.8 3.7% 16.51 EBO Ebos Group Ltd 3559 3.5% 1,919.95 TRP Tissue Repair 19 2.7% 11.19 EMV Emvision Medical 174 2.4% 149.23 SNZ Summerset Grp Hldgs 1044 2.3% 2,414.13 NEU Neuren Pharmaceut. 1411 1.7% 1,811.96 SPL Starpharma Holdings 8.8 1.1% 36.39 PME Pro Medicus Limited 28508 1.1% 15,301.07 MYX Mayne Pharma Ltd 500 1.0% 381.86 SHL Sonic Healthcare 2679 0.4% 12,836.39 1AD Adalta Limited 0.2 0.0% 2.14 AGH Althea Group 2.5 0.0% 20.56 ANR Anatara Ls Ltd 0.5 0.0% 1.07 CHM Chimeric Therapeutic 0.4 0.0% 9.07 DOC Doctor Care Anywhere 10.5 0.0% 42.16 DXB Dimerix Ltd 57.5 0.0% 346.85 EOF Ecofibre Limited 2 0.0% 7.58 EPN Epsilon Healthcare 2.4 0.0% 8.29 ICR Intelicare Holdings 0.7 0.0% 2.92 MEM Memphasys Ltd 0.5 0.0% 8.93 TD1 Tali Digital Limited 0.1 0.0% 4.10 CTE Cryosite Limited 74.5 -0.7% 36.36 FPH Fisher & Paykel H. 3363 -0.9% 6,557.10 SDI SDI Limited 83 -2.4% 97.47 ACL Au Clinical Labs 278 -2.5% 388.89 MSB Mesoblast Limited 165.5 -2.6% 1,810.36 NXS Next Science Limited 6.7 -2.9% 32.14 CSL CSL Limited 23948 -3.0% 115,358.67 AHC Austco Healthcare 29 -3.3% 107.40 CBL Control Bionics 2.9 -3.3% 9.43 LDX Lumos Diagnostics 2.7 -3.6% 19.46 CUV Clinuvel Pharmaceut. 1038 -3.7% 451.46 REG Regis Healthcare Ltd 784 -3.8% 1,167.64 ANN Ansell Limited 3029 -4.0% 4,490.73 SIG Sigma Health Ltd 299 -4.2% 17,142.40 RHC Ramsay Health Care 3669 -4.2% 7,017.07 IXC Invex Ther 8.9 -4.3% 6.69 PTX Prescient Ltd 4.4 -4.3% 33.02 PAR Paradigm Bio. 30.5 -4.7% 146.04 OCC Orthocell Limited 117.5 -5.2% 305.40 AYA Artryalimited 72 -5.3% 79.35 AVR Anteris Technologies 614 -5.5% 92.84 ONE Oneview Healthcare 25 -5.7% 190.96 FRE Firebrickpharma 6.2 -6.1% 14.37 AGN Argenica 76 -6.2% 95.43 TYP Tryptamine Ltd 3 -6.3% 43.06 TLX Telix Pharmaceutical 2442 -6.4% 7,003.27 AFP Aft Pharmaceuticals 243 -6.5% 254.83 CDX Cardiex Limited 4 -7.0% 22.00 PGC Paragon Care Limited 36.5 -7.6% 620.74 AVH Avita Medical 171.5 -7.8% 113.37 MVF Monash IVF Group Ltd 70.5 -7.8% 280.54 RAC Race Oncology Ltd 117.5 -8.2% 203.28 1AI Algorae Pharma 0.55 -8.3% 8.44 RAD Radiopharm 2.2 -8.3% 53.21 PNV Polynovo Limited 119.5 -8.8% 829.01 NAN Nanosonics Limited 405 -8.8% 1,155.80 VIT Vitura Health Ltd 6.2 -8.8% 41.72 IMC Immuron Limited 6.1 -9.0% 15.21 ATH Alterity Therap Ltd 1 -9.1% 91.27 PER Percheron 1 -9.1% 10.33 VHL Vitasora Health Ltd 3.9 -9.3% 61.50 TRJ Trajan Group Holding 71.5 -9.5% 111.24 ECS ECS Botanics Holding 0.9 -10.0% 11.66 LGP Little Green Pharma 9.9 -10.0% 33.44 HLS Healius 78.5 -10.3% 544.60 M7T Mach7 Tech Limited 33 -10.8% 82.02 MDR Medadvisor Limited 8.1 -11.0% 53.11 CVB Curvebeam Ai Limited 7.1 -11.3% 23.76 RHT Resonance Health 3.9 -11.4% 18.84 IBX Imagion Biosys Ltd 1.1 -12.0% 2.42 IME Imexhs Limited 29 -12.1% 15.56 BMT Beamtree Holdings 25 -12.3% 69.64 MX1 Micro-X Limited 4.9 -12.5% 32.69 IMR Imricor Med Sys 152 -12.6% 496.69 ZLD Zelira Therapeutics 44 -12.9% 5.23 IMU Imugene Limited 44.2 -13.3% 104.54 LTP Ltr Pharma Limited 29 -13.4% 36.39 BOT Botanix Pharma Ltd 32 -13.5% 605.72 CMP Compumedics Limited 25.5 -13.6% 49.02 GLH Global Health Ltd 6.8 -13.9% 3.92 PSQ Pacific Smiles Grp 154.5 -14.4% 239.20 RGT Argent Biopharma Ltd 8.1 -14.7% 5.77 AT1 Atomo Diagnostics 1.4 -15.2% 10.32 IDT IDT Australia Ltd 8.9 -15.2% 40.82 EYE Nova EYE Medical Ltd 11 -15.4% 32.68 CC5 Clever Culture 1.6 -15.8% 30.03 UCM Uscom Limited 1.6 -15.8% 4.01 IMM Immutep Ltd 24 -15.8% 350.49 IIQ Inoviq Ltd 37 -15.9% 41.30 BDX Bcaldiagnostics 6.3 -16.0% 24.52 MVP Medical Developments 54.5 -16.2% 61.40 CYP Cynata Therapeutics 15 -16.7% 38.41 PCK Painchek Ltd 4.5 -16.7% 73.68 RHY Rhythm Biosciences 5.4 -16.9% 15.34 UBI Universal Biosensors 3.5 -18.6% 10.43 RCE Recce Pharmaceutical 29 -19.4% 82.19 BIT Biotron Limited 0.2 -20.0% 2.65 BP8 Bph Global Ltd 0.2 -20.0% 2.10 SNT Syntara Limited 5.3 -20.9% 82.87 OIL Optiscan Imaging 11 -21.4% 100.24 PIQ Proteomics Int Lab 32.5 -23.5% 59.69 GSS Genetic Signatures 36.5 -24.0% 86.31 CYC Cyclopharm Limited 91 -24.2% 102.25 VFX Visionflex Group Ltd 0.15 -25.0% 6.74 NOX Noxopharm Limited 5.4 -26.0% 15.20 HIQ Hitiq Limited 1.4 -26.3% 6.90 CAN Cann Group Ltd 1 -28.6% 7.00 NTI Neurotech Intl 1.5 -28.6% 18.89 4DX 4Dmedical Limited 24 -29.4% 114.05 AVE Avecho Biotech Ltd 0.35 -30.0% 12.69 ACR Acrux Limited 1.6 -30.4% 7.34 ADR Adherium Ltd 0.4 -33.3% 4.49 PAB Patrys Limited 0.1 -33.3% 2.37 VBS Vectus Biosystems 4 -33.3% 2.02 ILA Island Pharma 14 -37.8% 30.69 TRI Trivarx Ltd 0.8 -38.5% 4.96 OSX Osteopore Limited 1.1 -38.9% 2.20 TRU Truscreen 1.6 -40.7% 11.75 MAP Microbalifesciences 8.5 -45.2% 43.78 HMD Heramed Limited 0.7 -46.2% 9.63 Amplia Therapeutics (ASX:ATX) rose 300% in June after a series of positive announcements including confirmed pathological complete responses recorded in two advanced (metastatic) pancreatic cancer patient as part of its ACCENT trial. The trial is investigating Amplia's best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane in patients with metastatic pancreatic cancer. Amplia also announced in June it had received US ethics approval of the protocol for its forthcoming Phase II clinical trial of narmafotinib in combination with the chemotherapy FOLFIRINOX in advanced pancreatic cancer. NeuroScientific Biopharmaceuticals (ASX:NSB) was up 50% in June after announcing it had acquired 100% of Perth-based unlisted company Isopogen WA, which owns or holds the rights to commercialise the patented StemSmart stem cell technology. Furthermore, Neuroscientific said previous clinical data showed StemSmart was effective in preventing graft-versus-host disease (GvHD), a common complication of bone-marrow transplants. A phase I clinical trial in adults with steroid-refractory GVHD, and a series of children treated on compassionate grounds for steroid-refractory GVHD found the majority of adults and children responded to StemSmartTM with a complete or partial resolution of symptoms and improved survival. Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) rose 15.7% in June after a series of positive announcements including positive topline data from two trials. Its diagnostic phase II trial DISCO confirmed that Cu-SARTATE was safe and highly effective compared to standard-of-care imaging at detecting lesions in patients with neuroendocrine tumours. Topline results from Clarity's Phase II SABRE trial showed that Cu-SAR-Bombesin was safe, well tolerated, and effective at detecting prostate cancer in patients with biochemical recurrence who had negative or unclear results on standard scans, including PSMA PET. Neurizon Therapeutics (ASX:NUZ) rose 14.8% with a series of positive announcements including positive trial results for its lead drug candidate NUZ-001. Preclinical data demonstrated significant neuroprotective effects of NUZ-001 and its active metabolite NUZ-001 Sulfone, in a zebrafish model of Huntington's disease. Neurizon also reported encouraging new rodent preclinical pharmacokinetic (PK) data for NUZ-001 and NUZ-001 Sulfone, showing it effectively crosses the blood-brain barrier. The ability of therapeutics to access the central nervous system remains a major barrier in treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis, the most common form of motor neurone disease, for which the company is focused. At Stockhead, we tell it like it is. While Neurizon Therapeutics is a Stockhead advertiser, the company did not sponsor this article.
